Mochras Gum: The Astringent, Diarrhea and Bleeding Tradition
Mochras — the dried resinous gum that oozes from cuts in the bark of Bombax ceiba — is the single material with the deepest formal standing in classical Ayurveda: a named grahi (binding, astringent) drug used for diarrhea, dysentery and abnormal bleeding. It is also, honestly, the thinnest part of this tree by PubMed-indexed research volume — exactly one gum-specific pharmacology paper exists, published in 2025. That thinness is itself the finding this page has to report, alongside one genuinely new and directly relevant 2024 result, and a real, informative contradiction from the flower, covered on its own page, that runs in the opposite pharmacological direction.
Table of Contents
- The Astringent Tradition: What Mochras Is Used For
- The Mechanism: Tannins and Protein Precipitation
- The One Gum-Specific Study: Antiulcer Activity (Upadhyay 2025)
- A Second, Part-Ambiguous Finding: "Shalmali" Extract on Human Endometrial Cells
- The Flower Contradicts the Gum — and That Is Informative
- A Leaf Finding That Is Not Gum Evidence
- What Is Genuinely Absent: A Real Diarrhea or Dysentery Trial
- What Is Genuinely Absent: A Real Menorrhagia Trial
- Cautions and Practical Guidance
- Key Research Papers
- Connections
The Astringent Tradition: What Mochras Is Used For
Classical Ayurvedic pharmacology classes mochras as grahi — a binding, astringent drug — and assigns it three related traditional uses: checking diarrhea, checking dysentery, and checking abnormal bleeding, most often heavy menstrual bleeding (menorrhagia). All three uses share one proposed mechanism: astringency, the same property that makes strong tea or unripe fruit pucker the mouth.
This tradition is old, specific, and consistently recorded across Ayurvedic sources. None of that establishes efficacy on its own; it establishes what claim is actually being made, which is the necessary first step before asking what evidence exists for it.
The Mechanism: Tannins and Protein Precipitation
The hub page for this plant already identifies tannins as the most plausible chemical basis for the gum's astringency, and the mechanism is real, general pharmacognosy: tannins cross-link and precipitate surface proteins on contact with a mucous membrane, producing a thin, tightened layer that can reduce secretion and oozing from small vessels. A 2025 study of astringent compounds generally (not specific to this plant) found this same protein-binding action, mediated substantially by proline-rich proteins, underlies the sensory and physical effects of astringent compounds on oral mucosa — useful as general confirmation of how astringency works at the molecular level, not as evidence that this specific gum, at any specific dose, controls diarrhea or bleeding in a person. Mechanism plausibility and demonstrated clinical effect are different claims, and the gap between them is the actual subject of this page.
The One Gum-Specific Study: Antiulcer Activity (Upadhyay 2025)
Searching PubMed for every plausible combination of Bombax ceiba and "gum" returns two results. One is a 2026 materials-chemistry paper using the gum as an industrial dye-removal adsorbent — irrelevant to any health claim, mentioned here only so a reader who finds it separately understands what it is. The other is the one real pharmacology paper this material has: Upadhyay and colleagues, ACS Omega, 2025, "An Integrative Omics and Network Pharmacology Approach to Evaluate the Antiulcer Activity of Bombax ceiba L. Gum in Rats."
The gum was tested orally in rats with experimentally induced gastric ulcers. It reduced gastric juice volume, free and total acidity, and the ulcer index, while increasing gastric pH — a real, positive, physiological result on validated ulcer-model endpoints. LC-MS/MS metabolomics identified alkaloids, flavonoids and glycosides in the gum, and network pharmacology plus molecular docking pointed to interactions with EGFR, SRC, COX-2 and matrix metalloproteinases — proteins with known roles in gastric mucosal healing.
What this is, and is not. This is a real, recent, mechanistically detailed rat efficacy study — more rigorous than a simple screening assay. It concerns gastric ulcer protection, which is related to but distinct from the traditional diarrhea/dysentery claim: reducing gastric acid and protecting the stomach lining is a different physiological target from binding intestinal contents further down the gut. It is one study, unreplicated, in rats, and it is the only reason this section of the page exists at all. It is also not mentioned anywhere on this plant's main hub page, which still describes the gum's evidence as limited to antimicrobial screening — this 2025 finding is new enough, and specific enough, that it belongs in the fuller picture.
A Second, Part-Ambiguous Finding: "Shalmali" Extract on Human Endometrial Cells
A 2024 Cureus paper is directly relevant to the bleeding side of the traditional claim, and deserves inclusion with one important caveat stated up front: its abstract describes the test material only as "Shalmali (Bombax ceiba) extract" — Shalmali being the Sanskrit name for the whole tree — without specifying which plant part supplied it. It is included here, under the gum article, because the traditional bleeding claim belongs specifically to mochras; a reader should know that connection is inferred, not stated by the paper itself.
The study treated a human endometrial stromal cell line (T HESC) with Shalmali extract and measured expression of three genes relevant to uterine bleeding: ESR1 (estrogen receptor), CD56, and SDF-1. Treatment produced a dose-dependent decrease in ESR1 and CD56 expression and an increase in SDF-1 (a marker associated with tissue repair). The authors compared these gene-expression changes against tranexamic acid — a real, guideline-recommended drug for heavy menstrual bleeding — and reported similar effects on the genes measured.
How to weigh this. Testing on a human-derived cell line is methodologically a step above a rodent whole-animal study on one axis (human cell biology rather than animal), and a step below one on another (an immortalized cell line in a dish, not a bleeding patient). A gene-expression change comparable to tranexamic acid's is not the same claim as a clinical bleeding outcome comparable to tranexamic acid's — gene expression is an intermediate marker, and the paper itself calls for further mechanistic and long-term safety research before any clinical extrapolation. Combined with the part ambiguity above, this is genuinely interesting and genuinely not a clinical result.
The Flower Contradicts the Gum — and That Is Informative
This site's Flower research page (linked in Connections below) covers a 2023 study in which Bombax ceiba flower aqueous extract significantly relieved loperamide-induced constipation in mice — increasing fecal water content, stool frequency and gastrointestinal transit rate, and raising motilin, gastrin and substance P (hormones that speed gut motility) while lowering somatostatin (which slows it). A second 2026 study found flower-derived polysaccharide protective against DSS-induced colitis in mice, restoring gut barrier function and reducing inflammation.
Both are gut-motility-and-barrier-protective, prokinetic-leaning findings. The gum's traditional claim is the opposite: astringent, binding, anti-motility, used specifically against diarrhea. Two parts of the same tree, pointing in opposite physiological directions on gut motility, is not a contradiction that needs resolving — it is exactly what this plant's doctrine of "different parts, different uses" predicts, and it is precisely why a flower finding must never be allowed to support a gum claim, or vice versa. A reader who encounters "Bombax ceiba is good for the gut" stated without a named part should treat that sentence as meaningless until the part is specified.
A Leaf Finding That Is Not Gum Evidence
A 2024 Heliyon paper (Taher and colleagues) profiled Bombax ceiba leaves computationally and phytochemically and reported pharmacological properties against oxidation, hyperglycemia, pain, and diarrhea, among leaf-extract activities. This is the closest thing in the literature to a second "diarrhea" data point for this plant — and it concerns the leaf, prepared and tested separately from the gum, with no basis for assuming shared potency or even shared active constituents. It is mentioned here for completeness and to close off an easy misreading, not folded into the gum's evidence count.
What Is Genuinely Absent: A Real Diarrhea or Dysentery Trial
No trial — animal or human — has tested mochras gum against infectious diarrhea or dysentery using a validated antidiarrheal endpoint (stool frequency, stool consistency, time to resolution). The antiulcer finding above is a real, adjacent GI result; it is not that trial. For comparison, real trials of real interventions for pediatric acute diarrhea do exist and are run in exactly the geographic and clinical context where mochras is traditionally used — for example, a 2022 randomized, double-blind, placebo-controlled trial in India tested a Bacillus clausii probiotic added to standard oral rehydration therapy and zinc in children with acute diarrhea. Bombax ceiba gum was not one of the arms. Naming a real trial that could have included this material, and did not, is a sharper statement of absence than simply saying "no trials exist."
This absence matters clinically because of what treats diarrhea that actually works. Acute infectious diarrhea kills through dehydration, and the single intervention proven to prevent that death is oral rehydration solution — salt, sugar and clean water, in the correct ratio — regardless of the underlying cause. Nothing about mochras substitutes for it. Bloody diarrhea, high fever, or diarrhea in a small child or an older adult is a reason to seek medical care, not a reason to reach for an astringent gum instead.
What Is Genuinely Absent: A Real Menorrhagia Trial
Similarly, no trial has tested mochras against heavy menstrual bleeding using a clinical bleeding-outcome measure (menstrual blood loss, days of bleeding, hemoglobin change). The endometrial cell-line finding above is genuinely relevant and genuinely not this. Tranexamic acid, used as the comparator in that cell-line study, has real human trial evidence behind it for heavy menstrual bleeding, including systematic-review-level evidence on its use in bleeding disorders specifically.
Heavy menstrual bleeding has identifiable, often treatable causes — fibroids, adenomyosis, polyps, thyroid disease, bleeding disorders, and, critically, it both causes and is worsened by iron deficiency, which independently causes fatigue that is easy to misattribute to something else. Choosing an unverified traditional astringent instead of a diagnostic workup risks leaving a treatable cause untreated while iron stores continue to fall.
Cautions and Practical Guidance
- No clinical trial exists for mochras in diarrhea, dysentery, or heavy menstrual bleeding. The 2025 antiulcer rat study and the 2024 human-cell-line bleeding-marker study are real and relevant, but neither is a clinical trial in patients.
- Do not use mochras in place of oral rehydration therapy for diarrhea, particularly in children or older adults, or in place of a diagnostic workup for heavy menstrual bleeding.
- Do not assume flower- or leaf-derived findings on this plant apply to the gum. The flower's own research points toward the opposite gut-motility direction; see above.
- Product identity and dose are unstandardized. "Mochras" sold commercially has no accepted marker compound or extract ratio, consistent with the rest of this plant.
- Heavy-metal contamination is a documented risk across unregulated multi-ingredient Ayurvedic formulations generally, and applies to gum-containing products sourced from open markets.
- Pregnancy and breastfeeding: no safety data exist; avoid.
Key Research Papers
- Upadhyay SS et al. (2025). An Integrative Omics and Network Pharmacology Approach to Evaluate the Antiulcer Activity of Bombax ceiba L. Gum in Rats. ACS Omega, 10(48):59044-59055. The one gum-specific pharmacology paper this material has. — PubMed
- P A et al. (2024). Evaluation of In-Vitro Studies of the Shalmali Extract on Human Endometrial Stromal Cells. Cureus, 16(5):e60699. Part not specified in the abstract; tranexamic acid comparator; gene-expression endpoints, not a clinical outcome. — PubMed
- Taher MA et al. (2024). Phyto-pharmacological and computational profiling of Bombax ceiba Linn. Leaves revealed pharmacological properties against oxidation, hyperglycemia, pain, and diarrhea. Heliyon. Leaf, not gum — cited to close off a likely misreading, not as gum evidence. — PubMed
- Wang L et al. (2023). Therapeutic effects of Bombax ceiba flower aqueous extracts against loperamide-induced constipation in mice. Pharmaceutical Biology, 61(1):125-134. Flower, opposite motility direction — the contradiction discussed above. — PubMed
- Zhang Q et al. (2026). Polysaccharides From Bombax ceiba Flower by Deep Eutectic Solvent Based Three-Phase Partitioning and Their Protective Effects Against DSS-Induced Colitis in Mice. Chemistry & Biodiversity, 23(3):e03434. Flower, gut-protective, not gum evidence. — PubMed
- Lahiri KR et al. (2022). Efficacy and safety of Bacillus clausii probiotic combined with oral rehydration therapy and zinc in acute diarrhea in children: a randomized, double-blind, placebo-controlled study in India. Tropical Diseases, Travel Medicine and Vaccines. Real RCT, same geographic and clinical context; did not include this plant. — PubMed
- Masood R et al. (2025). How should abnormal uterine bleeding be managed in people with bleeding disorders: a systematic review of the literature and thematic synthesis. Research and Practice in Thrombosis and Haemostasis. Real evidence base for tranexamic acid and AUB management, for comparison. — PubMed
- Ammam I et al. (2025). Investigating the influence of astringent compounds on oral lubrication and the protective role of proline-rich proteins. Scientific Reports. General astringency mechanism, not species-specific. — PubMed